

**Table 3-1: Demographic, clinical and laboratory parameters of the studied groups.**

	Group I n = 48		Group II n = 27		Controls n = 20	
<b>Age (years):</b>						
Mean + S D	5.33 + 2.82		6.24 + 2.35		6.38 + 2.62	
Range	(1.3 – 13)		(2.1 – 11.5)		(2.1 – 11.5)	
<b>Sex :</b>						
Males (n %)	33	(68.7)	21	(77.8)	14	(70)
Females (n %)	15	(31.3)	6	(22.2)	6	(30)
<b>SBP (mmHg):</b>						
Mean + SD	104.06 + 13.63		87.05 + 10.70		85.9 + 10.6	
Range	(70 – 130)		(50 – 110)		(50 – 100)	
<b>Haemturia :</b>						
- Ve (n %)	33	(68.7)	0	(0)	0	(0)
+ Ve (n %)	15	(31.3)	0	(0)	0	(0)
<b>Proteinuria (g/m<sup>2</sup>/d):</b>						
Mean + SD	2.55 + 1.06		0.43 + .070		0.40 + .050	
Range	(1.2 – 4.8)		(0.3 – 0.8)		(0.2 – 0.7)	
<b>Serum albumin (g/dl):</b>						
Mean + SD	1.93 + 0.52		3.56 + 1.80		3.86 + 1.83	
Range	(1.1 – 2.4)		(2.9 – 4.6)		(3.2 – 4.9)	
<b>Serum cholesterol (mg/dl):</b>						
Mean + SD	438.2 + 161.3		127.86 + 77.9		124.35 + 72.8	
Range	(123 – 844)		(98 – 157)		(95 – 150)	
<b>Serum creatinine (mg/dl):</b>						
Mean + SD	0.61 + 0.268		0.52 + 0.197		0.49 + 0.186	
Range	(0.2 – 2.2)		(0.15 – 1.4)		(0.1 – 1.1)	
<b>Serum C<sub>3</sub> (mg/dl):</b>						
Mean + SD	161.03 + 32.40		159.70 + 30.90		157.40 + 29.36	
Range	(100 – 244)		(100 – 235)		(98 – 223)	

\* SBP: systolic blood pressure

**Table 3-2: Expression of 5-LO mRNA in the studied groups.**

Studied groups	5- LO mRNA expression				Total
	-Ve		+ Ve		
	n	(%)	n	(%)	
Group I	0	(0)	48	(100)	48
Group II	21	(77.8)	6	(22.2)	27
Controls	20	(100)	0	(0)	20
Total	41		54		95

**Chi – square test**

**Between all groups:**       $X^2 = 69.88$        $P = .001^*$

**Fisher's exact test**

**Between each two:**

I      vs      II       $P = .001^*$

I      vs      controls       $P = .001^*$

II      vs      controls       $P = .69$

**Table 3-4: Grading of expression of 5-LO mRNA in steroid sensitive group.**

	5- LO mRNA expression					
	+Ve		++ Ve		+++Ve	
	n	(%)	n	(%)	n	(%)
<b>First attack</b>	0	(0)	6	(60)	4	(40)
<b>(n = 10)</b>						
<b>Infrequent relapsers</b>	0	(0)	3	(42.9)	4	(57.1)
<b>(n = 7)</b>						
<b>Frequent relapsers and steroid dependent</b>	1	(5.8)	5	(29.4)	11	(64.8)
<b>(n = 17)</b>						

**Chi – square test:**       $X^2 = 0.34$        $P = 0.48$       Non significant

**Table 3-5: Relation between histopathological findings of renal biopsy and expression of 5-LO mRNA in steroid resistant cases.**

	5- LO mRNA expression					
	+Ve		++ Ve		+++Ve	
	n	(%)	n	(%)	n	(%)
<b>(i) F S G S</b>	0	(0)	1	(20)	4	(80)
<b>(n = 5)</b>						
<b>(ii) D M P</b>	0	(0)	2	(50)	2	(50)
<b>(n = 4)</b>						
<b>(iii) M C N S</b>	1	(25)	2	(50)	1	(25)
<b>(n = 4)</b>						

### Chi – square test

#### Between all groups:

<b>I</b>	<b>vs</b>	<b>II</b>	$X^2 = 0.90$	$P = 0.63$
<b>I</b>	<b>vs</b>	<b>controls</b>	$X^2 = 0.20$	$P = 0.90$
<b>II</b>	<b>vs</b>	<b>controls</b>	$X^2 = 1.85$	$P = 0.39$

**Table 3-6: Expression of LTA<sub>4</sub> hydrolase mRNA in the studied groups.**

the studied groups:

Studied groups	LTA <sub>4</sub> hydrolase mRNA expression				Total
	-Ve		+ Ve		
	n	(%)	n	(%)	
Group I	0	(0)	48	(100)	48
Group II	13	(48.1)	14	(51.9)	27
Controls	20	(100)	0	(0)	20
Total	33		62		95

### Chi – square test

Between all groups:  $X^2 = 117.5$   $P = .001^*$

### Fisher's exact test

#### Between each two:

I vs II  $P = .001^*$

I vs controls  $P = .001^*$

II vs controls  $P = .001^*$

**Table 3-7: Grading of expression of  $LTA_4$  hydrolase mRNA in patients with steroid sensitive (group Ia) & steroid resistant (group Ib) active nephrotic syndrome.**

	LTA <sub>4</sub> hydrolase mRNA expression			
	++Ve		+++Ve	
	n	(%)	n	(%)
Group Ia	2	(5.9)	32	(94.1)
(n = 34)				
Group Ib	0	(0)	14	(100)
(n = 14)				

**Fisher's exact test:**

P = 0.35

Non significant.

**Table 3-8: Grading of expression of  $LTA_4$  hydrolase mRNA in steroid sensitive group.**

	<b><math>LTA_4</math> hydrolase mRNA expression</b>			
	<b>++Ve</b>		<b>+++Ve</b>	
	<b>n</b>	<b>(%)</b>	<b>n</b>	<b>(%)</b>
<b>* First attack</b>	0	(0)	10	(100)
<b>(n = 10)</b>				
<b>* Infrequent relapsers</b>	0	(0)	7	(100)
<b>(n = 7)</b>				
<b>* Frequent relapsers and steroid dependent</b>	2	(11.7)	15	(88.3)
<b>(n = 17)</b>				

**Chi – square test**

**Between all groups:**       $X^2 = 2.13$        $P = 0.34$       Non significant

**Table 3-9: Relation between histopathological findings of renal biopsy and expression of  $LTA_4$  hydrolase mRNA in steroid resistant cases.**

	<b><math>LTA_4</math> hydrolase mRNA expression (+++Ve)</b>	
	<b>n</b>	<b>(%)</b>
<b>(i) FSGS</b>	5	(100)
<b>(ii) DMP</b>	4	(100)
<b>(iii) MCNS</b>	4	(100)
<b>Total</b>	13	(100)



**Table 3-10: Kendall Tau correlation between clinical, laboratory parameters and 5-LO, LTA<sub>4</sub> hydrolase mRNA in active disease group**

	5-LO mRNA expression		LTA <sub>4</sub> hydrolase mRNA expression	
	r	P	r	P
Systolic blood pressure	- .11	0.59	0.06	0.61
Serum creatinine	0.17	0.10	0.17	0.08
Serum cholesterol	0.02	0.83	0.05	0.57
Serum C <sub>3</sub>	- .06	0.55	- .05	0.56

**Table 3-11: Relation between 5-LO mRNA expression and haematuria in active disease group.**


LTA <sub>4</sub> hydrolase mRNA expression	(+ Ve) haematuria		(- Ve) haematuria	
	n	(%)	n	(%)
+ Ve	2	(13.3)	0	(0)
++ Ve	5	(33.4)	14	(42.4)
+++ Ve	8	(53.3)	19	(57.6)
<b>Total</b>	<b>15</b>	<b>(100)</b>	<b>33</b>	<b>(100)</b>

**Chi – square test:**       $X^2 = 0.93$        $P = 0.33$       Non significant

**Table 3-12: Relation between  $LTA_4$  hydrolase mRNA expression and haemturia in active disease group.**

5-LO mRNA expression	(+ Ve) haemturia		(-Ve) haemturia	
	n	(%)	n	(%)
++ Ve	0	(0)	2	(6.1)
+++ Ve	15	(100)	31	(93.9)
<b>Total</b>	<b>15</b>	<b>(100)</b>	<b>33</b>	<b>(100)</b>

**Chi – square test:**       $X^2 = 0.95$        $P = 0.30$       Non significant



**Fig.(3.1) Kendall Tau Correlation between 24 hour urinary protein and 5-LO mRNA in active group..**




Fig.(3.2). Kendall Tau Correlation between 24 hour urinary protein and LTA<sub>4</sub> hydrolase mRNA in active group.

## ANALYSIS OF RESULTS

**Table 3-2:** Shows that all patients with active disease expressed 5-LO mRNA while only 6 patients (22.2%) of patients in remission expressed 5-LO mRNA. Non of the controls expressed 5-LO mRNA. There was a significant difference in expression of 5-LO mRNA between group I & group II ( $P = .001^*$ ) and between group I & controls ( $P = .001^*$ ) while there was no significant difference in the expression of 5-LO mRNA between group II & controls.

**Table 3-3:** Shows that 19 patients (55.9%) of steroid sensitive group and 8 patients (57.1%) of steroid resistant group have high expression of 5-LO mRNA. Fourteen patients (41.2%) of steroid sensitive group and 5 patients (35.8%) of steroid resistant group moderately expressed 5-LO mRNA while 1 patient (2.9%) of steroid sensitive group and 1 patient (7.1%) of steroid resistant group weakly expressed 5-LO mRNA. There was no significant difference in the expression of 5-LO mRNA between steroid sensitive and steroid resistant group.

**Table 3-4:** Shows that 11 patients (64.8%) of frequent relapsers and steroid dependent group, 4 patients (57.1%) of infrequent relapsers group and 4 patients (40%) of 1<sup>st</sup> attack group have high expression of 5-LO mRNA. Six patients (60%) of 1<sup>st</sup> attack group, 3 patients (42.9%) of infrequent relapsers and 5 patients (29.4%) of frequent relapsers and steroid dependent group moderately expressed 5-LO mRNA while 1 patient (5.8%) of frequent relapsers and steroid dependent weakly expressed 5-LO mRNA. There was no significant deference in the expression of 5-LO mRNA between all groups of steroid sensitive patients.

**Table 3-5:** Shows that in patients whose renal biopsy revealed FSGS 4 patients (80%) highly expressed 5-LO mRNA and 1 patient (20%) moderately expressed 5-LO mRNA. In DMP 2 patient (50%) highly expressed 5-LO mRNA. In MCNS 1 patient (25%) highly expressed 5-LO mRNA, 2 patients (50%) moderately expressed 5-LO mRNA and 1 patient (25%) weakly expressed 5-LO mRNA. There was no significant difference in the expression of 5-LO mRNA between all patients with steroid resistant nephrotic syndrome whatever the result of their renal biopsy.

**Table 3-6:** Shows that all patients with active disease expressed LTA<sub>4</sub> hydrolase mRNA while 14 patients (51.9%) of patients in remission expressed LTA<sub>4</sub> hydrolase mRNA. None of the controls expressed LTA<sub>4</sub> hydrolase mRNA.

There was a significant difference in expression of LTA<sub>4</sub> hydrolase mRNA between group I & group II ( $p = .001^*$ ),  
 between group I & controls ( $p = .001^*$ ),  
 and between group II & controls ( $p = .001^*$ ).

**Table 3-7:** Shows that all patients of steroid resistant group and 32 patients (94.1%) of patients of steroid sensitive group highly expressed LTA<sub>4</sub> hydrolase mRNA while 2 patients (5.9%) of steroid sensitive group moderately expressed LTA<sub>4</sub> hydrolase mRNA. There was no significant difference in the expression of LTA<sub>4</sub> hydrolase mRNA between steroid sensitive and steroid resistant groups.

**Table 3-8:** Shows that all patients of 1<sup>st</sup> attack group and infrequent relapsers group and 15 patients (88.3%) of frequent relapsers and steroid dependent group highly expressed LTA<sub>4</sub> hydrolase mRNA while 2 patients (11.7%) of frequent relapsers and steroid dependent group moderately

expressed LTA<sub>4</sub> hydrolase mRNA. There was no significant difference in the expression of LTA<sub>4</sub> hydrolase mRNA between all groups of steroid sensitive patients.

**Table 3-9:** Shows that all patients highly expressed LTA<sub>4</sub> hydrolase mRNA whatever the result of their renal biopsy whether FSGS or DMP or MCNS.

**Table 3-10:** Shows that there was a weak positive correlation between 5-LO mRNA & LTA<sub>4</sub> hydrolase mRNA and serum creatinine, while there was no significant correlation between 5-LO, LTA<sub>4</sub> hydrolase mRNA and other clinical & laboratory parameters.

**Table 3-11:** Shows that there was no significant difference in grading of expression of 5-LO mRNA between patients having haematuria and those who did not have haematuria.

**Table 3-12:** Shows that there was no significant difference in grading of expression of LTA<sub>4</sub> hydrolase mRNA between patients having haematuria and those who did not have haematuria.

**Figure (3-1):** Shows significant positive correlation between the degree of proteinuria and expression of 5-LO mRNA ( $r = .27$ ,  $P = .027$ ).

**Figure (3-2):** Shows significant positive correlation between the degree proteinuria and expression of LTA<sub>4</sub> hydrolase mRNA ( $r = 0.44$ ,  $P = 0.001^*$ ).

**Figure (3-3):** Shows significant positive correlation between the expression of both 5-LO & LTA<sub>4</sub> hydrolase mRNA in active PNS patients ( $r = .77$ ,  $P = 0.001^*$ ).